

Oncogene controls stem cells in early embryonic development

In a process called diapause, many animal species delay the development of their embryos in order to ensure that their offspring is born at a possibly favorable time. Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM) have now shown that this process is regulated by the MYC oncogene. If MYC is turned off in mice, embryonic stem cells and early embryos enter a reversible biochemical state of dormancy. However, this does not affect their ability to differentiate into any cell type of the body. When MYC is reactivated, the dormant embryos are able to develop into healthy animals. These findings have been published in the latest issue of “Cell”.

After a gestation period of around ten months, fawns are born in early summer – when the weather is warm and food is plentiful for the mother. Six months would actually be enough for the embryo’s development, but then offspring from mating in the later portion of summer would be born in winter. Therefore, nature prolongs the gestation period by a hormone-regulated pause in the development of the early embryos. Many animal species use this process, called diapause, to adjust their reproduction to environmental conditions.

In their research on embryonic stem cells, Andreas Trumpp and colleagues have now discovered the factor that controls this developmental pause. Trumpp is head of a research department at the DKFZ and of Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM), which is based at the DKFZ and supported by the Dietmar Hopp Foundation.

It is known in many types of cancer that the more MYC they produce, the more aggressively the tumors grow. The scientists had noticed that MYC is also active in embryonic stem cells. In order to explore the role that the gene plays in these cells, the investigators obtained embryonic stem cells from mice whose MYC genes (c-MYC and N-MYC) they could selectively deactivate. The resulting embryonic MYC-depleted stem cells strongly reduced the activity of genes that play a role in cell division, cellular growth and metabolism. However, the dormant cells stayed alive and retained their identity as stem cells: they continued producing the important "stem cell factors" that enable them to differentiate into the more than 200 cell types of the body.

Using a chemical substance that inhibits MYC, the scientists were able to show that this biochemical dormancy is reversible. When they stopped giving the inhibitor, the cells immediately resumed RNA, protein and DNA synthesis and were able to proliferate infinitely.

Inhibiting MYC activity arrests embryonic development

“The biochemical dormancy of MYC-depleted stem cells reminded us strongly of the process of diapause, which has remained completely elusive so far,” says Roberta Scognamiglio, who is the first author of the study. “In this process, too, embryos in the early development state, called blastocysts, enter a dormant state without growth and almost without metabolism prior to nidation in the uterus.” In order to find out whether these two phenomena have the same cause, the researchers compared the activity of all genes in MYC-depleted embryonic stem

cells with those in diapaused mouse blastocysts. In both cases, the groups of genes that were inactive besides MYC primarily controlled protein synthesis and cell growth. The stem cell factors, however, continued to be produced unchanged.

When the researchers treated normal blastocysts in the Petri dish with the MYC inhibitor, they fell into a diapause-like state. These dormant embryos were subsequently transferred into surrogate mother mice and grew to become normal young animals.

“To induce diapause or to put embryonic stem cells into a dormant state, it is therefore sufficient to deactivate the MYC oncogene,” Trumpp summarizes. “This does not affect the potential of stem cells. This is a very special property of stem cells, because all other cell types die after MYC inhibition.”

Trumpp thinks that MYC can also have a disastrous effect on cancer stem cells, particularly on dormant metastasis stem cells. When they migrate through the bloodstream to distant organs, they may come under the influence of signaling molecules that form, for example, in inflammatory processes. These might stimulate their MYC production and thus cause them to grow into metastases. “We now try blocking MYC as a strategy to control these dangerous sleepers,” the stem cell researcher says.

A picture for this press release is available at:

<http://www.dkfz.de/de/presse/pressemitteilungen/2016/bilder/Trumpp-Cell-003.jpg>

Caption: Dormant mouse blastocyst. Source: Andreas Trumpp, DKFZ/HI-STEM

Roberta Scognamiglio, Nina Cabezas-Wallscheid, Marc Christian Thier, Sandro Altamura, Alejandro Reyes, Áine M. Prendergast, Daniel Baumgärtner, Larissa S. Carnevalli, Ann Atzberger, Simon Haas, Lisa von Paleske, Thorsten Boroviak, Philipp Wörsdörfer, Marieke A. G. Essers, Ulrich Kloz, Robert N. Eisenman, Frank Edenhofer, Paul Bertone, Wolfgang Huber, Franciscus van der Hoeven, Austin Smith and Andreas Trumpp: Myc Depletion Induces a Pluripotent Dormant State Mimicking Diapause. CELL 2016, DOI: 10.1016/j.cell.2015.12.033

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institute in Germany. At DKFZ, more than 1,000 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful. The staff of the Cancer Information Service (KID) offers information about the widespread disease of cancer for patients, their families, and the general public. Jointly with Heidelberg University Hospital, DKFZ has established the National Center for Tumor Diseases (NCT) Heidelberg, where promising approaches from cancer research are translated into the clinic. In the German Consortium for Translational Cancer Research (DKTK), one of six German Centers for Health Research, DKFZ maintains translational centers at seven university partnering sites. Combining excellent university hospitals with high-profile research at a Helmholtz Center is an important contribution to improving the chances of cancer patients. DKFZ is a member of the Helmholtz Association of National Research Centers, with ninety percent of its funding coming from the German Federal Ministry of Education and Research and the remaining ten percent from the State of Baden-Württemberg.

Contact:

Dr. Stefanie Seltmann
Head of Press and Public Relations
German Cancer Research Center
Im Neuenheimer Feld 280
D-69120 Heidelberg
T: +49 6221 42 2854
F: +49 6221 42 2968
presse@dkfz.de

Dr. Sibylle Kohlstädt
Press and Public Relations
German Cancer Research Center
Im Neuenheimer Feld 280
D-69120 Heidelberg
T: +49 6221 42 2843

F: +49 6221 42 2968
Email: presse@dkfz.de